Incidence of cervical cancer after several negative smear results by age 50: prospective observational study
- PMID: 19395420
- PMCID: PMC2673344
- DOI: 10.1136/bmj.b1354
Incidence of cervical cancer after several negative smear results by age 50: prospective observational study
Abstract
Objective: To determine the incidence of cervical cancer after several negative cervical smear tests at different ages.
Design: Prospective observational study of incidence of cervical cancer after the third consecutive negative result based on individual level data in a national registry of histopathology and cytopathology (PALGA).
Setting: Netherlands, national data. Population 218,847 women aged 45-54 and 445,382 aged 30-44 at the time of the third negative smear test.
Main outcome measures: 10 year cumulative incidence of interval cervical cancer.
Results: 105 women developed cervical cancer within 2 595,964 woman years at risk after the third negative result at age 30-44 and 42 within 1,278,532 woman years at risk after age 45-54. During follow-up, both age groups had similar levels of screening. After 10 years of follow-up, the cumulative incidence rate of cervical cancer was similar: 41/100,000 (95% confidence interval 33 to 51) in the younger group and 36/100,000 (24 to 52) in the older group (P=0.48). The cumulative incidence rate of cervical intraepithelial neoplasia grade I+ was twice as high in the younger than in the older group (P<0.001).
Conclusions: The risk for cervical cancer after several negative smear results by age 50 is similar to the risk at younger ages. Even after several negative smear results, age is not a good discriminative factor for early cessation of cervical cancer screening.
Conflict of interest statement
Competing interests: The department of public health of the Erasmus MC received a grant from GSK, a manufacturer of an HPV vaccine, for research on the cost effectiveness of HPV vaccination in 2007 and 2008. This research and manuscript were neither funded nor supported by GSK. RB has been participating since 1989 in the screening research group at the department. He has been affiliated with RAND since 2000. Since 2007, he has been a director of evidence based strategies-disease modelling and economic evaluation at Pfizer, who develop and sell various drugs for cancer and other diseases. This research and manuscript were neither funded nor supported by Pfizer.
Figures
Comment in
-
At what age should cervical screening stop?BMJ. 2009 Apr 24;338:b809. doi: 10.1136/bmj.b809. BMJ. 2009. PMID: 19395422 No abstract available.
Similar articles
-
Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study.BMJ. 2012 Oct 31;345:e6855. doi: 10.1136/bmj.e6855. BMJ. 2012. PMID: 23117059 Free PMC article.
-
No increased risk for cervical cancer after a broader definition of a negative Pap smear.Int J Cancer. 2008 Dec 1;123(11):2632-5. doi: 10.1002/ijc.23803. Int J Cancer. 2008. PMID: 18767046
-
Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.BMJ. 2016 Oct 4;355:i4924. doi: 10.1136/bmj.i4924. BMJ. 2016. PMID: 27702796 Clinical Trial.
-
Incidence of cervical intraepithelial neoplasia grade III, and cancer of the cervix uteri following a negative Pap-smear in an opportunistic screening.Acta Obstet Gynecol Scand. 1998 Feb;77(2):228-32. Acta Obstet Gynecol Scand. 1998. PMID: 9512333
-
Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force.Ann Intern Med. 2011 Nov 15;155(10):698-705, W216. doi: 10.7326/0003-4819-155-10-201111150-00377. Epub 2011 Oct 17. Ann Intern Med. 2011. PMID: 22006929 Review.
Cited by
-
Lightweight Low-Rank Adaptation Vision Transformer Framework for Cervical Cancer Detection and Cervix Type Classification.Bioengineering (Basel). 2024 May 8;11(5):468. doi: 10.3390/bioengineering11050468. Bioengineering (Basel). 2024. PMID: 38790335 Free PMC article.
-
Evaluation of PCR-Reverse Dot Blot Human Papillomavirus Genotyping Test in Predicting Residual/Recurrent CIN 2+ in Posttreatment Patients in China.Cancer Manag Res. 2020 Apr 1;12:2369-2379. doi: 10.2147/CMAR.S237490. eCollection 2020. Cancer Manag Res. 2020. PMID: 32308477 Free PMC article.
-
Effectiveness of cervical cancer screening at age 65 - A register-based cohort study.PLoS One. 2019 Mar 26;14(3):e0214486. doi: 10.1371/journal.pone.0214486. eCollection 2019. PLoS One. 2019. PMID: 30913262 Free PMC article.
-
Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009.Cancer. 2014 Jul 1;120(13):2032-8. doi: 10.1002/cncr.28548. Epub 2014 May 12. Cancer. 2014. PMID: 24821088 Free PMC article.
-
Cervical cancer screening in older women: new evidence and knowledge gaps.PLoS Med. 2014 Jan;11(1):e1001586. doi: 10.1371/journal.pmed.1001586. Epub 2014 Jan 14. PLoS Med. 2014. PMID: 24453947 Free PMC article.
References
-
- Baay MF, Smits E, Tjalma WA, Lardon F, Weyler J, Van Royen P, et al. Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women. Int J Cancer 2004;108:258-61. - PubMed
-
- Cruickshank ME, Angus V, Kelly M, McPhee S, Kitchener HC. The case for stopping cervical screening at age 50. Br J Obstet Gynaecol 1997;104:586-9. - PubMed
-
- Flannelly G, Monaghan J, Cruickshank M, Duncan I, Johnson J, Jordan J, et al. Cervical screening in women over the age of 50: results of a population-based multicentre study. Br J Obstet Gynaecol 2004;111:362-8. - PubMed
-
- Gustafsson L, Sparen P, Gustafsson M, Pettersson B, Wilander E, Bergstrom R, et al. Low efficiency of cytologic screening for cancer in situ of the cervix in older women. Int J Cancer 1995;63:804-9. - PubMed
-
- Ogilvie D. Early discharge of low-risk women from cervical screening. J Public Health Med 2001;23:272-7. - PubMed